27Jun/19
Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia
Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…